BLFS (BioLife Solutions) Momentum Rank: 10 (As of Aug. 05, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $32.51
GF Value $29.13
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Momentum Rank?

BioLife Solutions BLFS +1.12% 72 Momentum Rank is 10 as of Aug. 05, 2026, which is 67% above its 10-year median of 6.00. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $29.13 (Modestly Overvalued). The stock has 5 warning signs investors should review.

BioLife Solutions has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

BioLife Solutions Momentum Rank Related Terms

BLFS vs AZTA, KMTS, STAA: Momentum Rank Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLife Solutions Momentum Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Momentum Rank distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Momentum Rank falls into.


BLFS
72GF Score
BioLife Solutions Inc BLFS
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
BioLife Solutions (BLFS) has a Momentum Rank of 10 as of Aug. 05, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on BioLife Solutions and its competitors. This is 67% above median its historical median of 6.00. Over the past decade, BioLife Solutions' Momentum Rank has ranged from 1.00 to 10.00.
Is BioLife Solutions' Momentum Rank too high?
BioLife Solutions' current Momentum Rank of 10 is 67% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Momentum Rank compare to AZTA and KMTS?
BioLife Solutions' Momentum Rank of 10 can be compared against companies in the Medical Devices & Instruments industry. Historically, BioLife Solutions' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Devices & Instruments company?
A good Momentum Rank depends on the Medical Devices & Instruments industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current Momentum Rank is 10, which is 67% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.13, compared to a current price of $32.51 — trading 11.6% above its estimated fair value. The current Momentum Rank is 10, which is 67% above median its 10-year median of 6.00. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Momentum Rank is 10 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $32.51 is trading 11.6% above its estimated GF Value™ of $29.13. GuruFocus considers BioLife Solutions to be Modestly Overvalued.

Key valuation signals for BLFS:

  • Momentum Rank: 10 (67% above median its 10-year median of 6.00)
  • GF Value™: $29.13 vs. price of $32.51 (11.6% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.51
Price
$29.13
GF Value